Orphazyme fails trial in muscle wasting disease

Orphazyme's drug arimoclomol has not shown the desired effect in a pivotal phase II/III trial involving 150 patients with inclusion body myositis (IBM).

Photo: Orphazyme/PR

On Monday morning, Orphazyme was forced to announce that the firm had not seen the results from the phase II/III trial with arimoclomol as treatment for inclusion body myositis (IBM) for which the company management had hoped.

The study had no safety issues, but the company informs that it neither met its primary, nor its secondary endpoints.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs